Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Russell Riehl

Cardiovascular Disease Rockport, ME Medical Doctor

NPI 1891144317 CMS profile 5699281

4 Glen Cove Dr Ste 108, Rockport, ME 04856

Open in the dashboard

General payments

$2,202

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Riehl of Rockport, ME is reported in the CMS Open Payments database as having received $2,202 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81 4
2024 General $300 15
2023 General $757 51
2022 General $388 29
2021 General $485 10
2020 General $14 1
2019 General $176 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Riehl
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Russell Riehl were reported at $81. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Russell Riehl Cardiovascular Disease median Middle half National median
2019 $176 $450 $127–$1,392 $163
2020 $14 $242 $77–$751 $114
2021 $485 $335 $101–$1,037 $132
2022 $388 $395 $121–$1,211 $149
2023 $757 $443 $136–$1,283 $160
2024 $300 $450 $136–$1,323 $164
2025 $81 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $454 26 payments
  2. Medtronic, Inc. $397 4 payments
  3. E.R. Squibb & Sons, L.L.C. $303 15 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $302 25 payments
  5. Amgen Inc. $211 13 payments
  6. Chiesi USA, Inc. $167 9 payments
  7. Janssen Pharmaceuticals, Inc $81 5 payments
  8. Pfizer Inc. $67 5 payments
  9. Abiomed $51 3 payments
  10. Edwards Lifesciences Corporation $32 2 payments
  11. Other $137 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,810 112 payments
  2. Education $392 3 payments
Products named General payments · program years 2019–2025
  1. Micra $372 2 payments
  2. LEQVIO $313 24 payments
  3. ENTRESTO Cardiology/Vascular Diseases $313 24 payments
  4. CAMZYOS $303 15 payments
  5. LifeVest $302 25 payments
  6. Repatha $211 13 payments
  7. CLEVIPREX $143 8 payments
  8. ENTRESTO Cardiovascular $141 2 payments
  9. KENGREAL $133 7 payments
  10. XARELTO $81 5 payments
  11. Other $390 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

271

Median for Cardiology: 2,533

Drug cost

$69,351

Median for Cardiology: $485,213

Branded share of claims

29.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 43 $51,017
Farxiga Dapagliflozin Propanediol Brand 15 $9,432
Repatha Sureclick Evolocumab Brand 12 $6,627
Atorvastatin Calcium Generic 31 $536
Metoprolol Succinate Generic 41 $517
Rosuvastatin Calcium Generic 24 $447
Carvedilol Generic 32 $296
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 11 $166
Lisinopril Generic 13 $99
Ezetimibe Generic 12 $90

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$18,587

Medicare's payments for the services billed

Medicare patients

339

Average age 77

Services billed

650

163 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Atrial fibrillation 40%
Ischemic heart disease 37%
Chronic kidney disease 32%
Heart failure 28%
COPD 23%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $109
$109 — —
Repatha
  • Amgen Inc. $50
$50 12 —
KENGREAL
  • CHIESI USA, INC. $24
$24 — —
Ozempic
  • Novo Nordisk Inc $23
$23 — —
CLEVIPREX
  • CHIESI USA, INC. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record